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Abstract 
Following a spinal cord injury (SCI) a growth aversive environment forms, consisting of a 
fibroglial scar and inhibitory factors, further restricting the already low intrinsic growth 
potential of injured adult central nervous system (CNS) neurons. Previous studies have shown 
that local administration of the microtubule-stabilizing drug paclitaxel or epothilone B (Epo 
B) reduce fibrotic scar formation and axonal dieback as well as induce axonal
growth/sprouting after SCI. Likewise, systemic administration of Epo B promoted functional 
recovery. In this study, we investigated the effects of epothilone D (Epo D), an analog of Epo 
B with a possible greater therapeutic index, on fibrotic scarring, axonal sprouting and 
functional recovery after SCI. Delayed systemic administration of Epo D after a moderate 
contusion injury (150kDyn) in female Fischer 344 rats resulted in a reduced number of 
footfalls when crossing a horizontal ladder at 4 and 8 weeks post injury. Hindlimb motor 
function assessed with the BBB open field locomotor rating scale and Catwalk gait analysis 
were not significantly altered. Moreover, formation of laminin positive fibrotic scar tissue and 
5-HT positive serotonergic fiber length caudal to the lesion site were not altered after
treatment with Epo D. These findings recapitulate a functional benefit after systemic 
administration of a microtubule-stabilizing drug in rat contusion SCI.  
Keywords: 
epothilone D, microtubule stability, spinal cord injury, functional recovery, moderate 
contusion 
Highlights 
 Systemic Epo D injections are beneficial after moderate spinal cord injury
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 Epo D does not enhance serotonergic axon growth below the lesion
 Epo D has no neuroprotective effects
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Introduction 
Traumatic spinal cord injury (SCI) results in sensorimotor and autonomic deficits due 
to the disruption of descending motor and ascending sensory pathways. After the initial insult, 
secondary degeneration involving various pathophysiological mechanisms leads to the 
formation of fluid filled cavities, loss of grey and white matter and the formation of a glial 
and fibrotic scar. Furthermore, retrograde degeneration including dieback of axons, formation 
of retraction bulbs and disorganization of microtubule exacerbate the primary injury (Erturk et 
al., 2007). 
Stabilizing microtubules inhibits proliferation of cells, which has been exploited in 
drug development for cancer therapies. The stabilization of microtubules in neurons is vital 
for axonal transport and function (Brunden et al., 2010; Garcia and Cleveland, 2001; Goedert 
and Jakes, 2005). Therefore microtubule stabilizing drugs have been investigated in animal 
models of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and 
schizophrenia to abate degenerating axons and promote regeneration (Andrieux et al., 2006; 
Ballatore et al., 2012; Brunden et al., 2010; Cartelli et al., 2013; Daoust et al., 2014; Fournet 
et al., 2012).  
The effect of the microtubule stabilizing anti-cancer drug paclitaxel on 
microtubule dynamics is concentration-dependent. High concentrations, which are typically 
used for cancer treatment, over-stabilize microtubules, thus blocking microtubule dynamics, 
which in turn suppresses axon elongation (Erturk et al., 2007; Sengottuvel and Fischer, 2011; 
Sengottuvel et al., 2011). In contrast, low concentrations of paclitaxel lead to moderate 
microtubule stabilization in axonal growth cones, which still allows microtubule 
polymerization at the plus end (Derry et al., 1995; Derry et al., 1997; Witte et al., 2008), 
enhances axonal growth in cultured neurons (Hellal et al., 2011; Sengottuvel et al., 2011) and 
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preserves microtubule stability and bundling in injured spinal cord axons (Erturk et al., 2007). 
In rodent SCI and optic nerve injury models, paclitaxel inhibits fibrotic scarring and 
deposition of inhibitory CSPGs (Chondroitin sulfate proteoglycans) in the lesion site and 
promotes axonal regeneration as well as functional recovery (Erturk et al., 2007; Hellal et al., 
2011; Perez-Espejo et al., 1996; Popovich et al., 2014; Sengottuvel et al., 2011). Moreover, 
low paclitaxel concentrations have been shown to at least transiently delay macrophage 
infiltration and astrocyte proliferation around the lesion site after optic nerve injury 
(Sengottuvel and Fischer, 2011; Sengottuvel et al., 2011). 
In contrast to paclitaxel, which cannot cross the blood-brain barrier (BBB), some 
epothilones are BBB permeable while possessing comparable biological effects and sharing a 
common binding site (Giannakakou et al., 2000). Thus they are more suitable candidates for 
treatment of neurological disorders and injuries. Epothilones already have U.S. Food and 
Drug Administration (FDA) approval for cancer treatment (Brogdon et al., 2014; Cheng et al., 
2008; Goodin et al., 2004). 
Both analogs, epothilone B (Epo B) and epothilone (Epo D), act in a dose dependent 
manner on microtubule stabilization similar to paclitaxel (Altmann et al., 2000a; Altmann et 
al., 2000b; Ballatore et al., 2012; Cheng et al., 2008; Goodin et al., 2004; Muhlradt and Sasse, 
1997). A recent study using an in vitro axotomy model showed that the exposure of neurons 
to Epo D increased axonal sprouting without affecting their viability or metabolic function 
(Brizuela et al., 2015). The application of Epo D in animal models of tauopathies such as 
Alzheimer’s disease improved axonal transport, decreased tau neuropathology, reduced 
neuronal loss and axonal dystrophy paralleled by amelioration of cognitive deficits (Barten et 
al., 2012; Brill et al., 2016; Brunden et al., 2010; Lou et al., 2014; Zhang et al., 2012). The 
systemic administration of Epo B in a moderate rat spinal cord contusion injury reduced 
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fibrotic scar formation by interfering with fibroblast migration to the lesion site, promoted 
axonal growth by stabilizing microtubules and reduced the number of footfalls when crossing 
a regular spaced horizontal ladder (Ruschel et al., 2015). 
Given that clinical trials Epo D reported a better safety profile than Epo B including a 
greater therapeutic index (Chou et al., 1998; Fumoleau et al., 2007; Goodin et al., 2004) we 
investigated potential effects of Epo D in a rat contusion SCI model. We observed that 
systemic administration of Epo D results in improved skilled hindlimb function after a 
moderate spinal cord contusion injury.  
Methods 
Animal subjects 
Adult female Fischer 344 rats (Charles River Deutschland GmbH, Sulzfeld, Germany, 
Envigo, Cambridgeshire, UK; Janvier Labs, Saint-Berthevin Cedex, France) weighing 160-
180g were used for all in vivo experiments. Experiments were carried out in accordance with 
the European Union Directive (2010/63/EU) and institutional guidelines. Animals had ad 
libitum access to food and water throughout the study.  
Surgical procedures and treatment 
For all surgical procedures, animals were anesthetized using a cocktail of ketamine       
m       edis ar  As he er   erma       lazi e        m       a er   e er  se   
 erma     a d a e r mazi e        m       a   i- e a    sseld r , Germany) in 0.9% 
sterile saline solution. A total of 34 rats received a spinal cord contusion injury at midthoracic 
level Th9 (representing spinal level Th11) using the Infinite Horizon (IH) Impactor SCI 
device (Precision Systems & Instrumentation, Lexington, KY, USA) with an impact force of 
150 kilodynes (kDyn) as previously described (Scheff et al., 2003). Postoperatively, animals 
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were kept warm, and buprenorphine (0.03 mg/kg; Reckitt Benckiser, Mannheim, Germany, 
for 2 days postoperatively twice a day) and ampicillin (167 mg/kg; Ratiopharm, Ulm, 
Germany, twice a day) was given subcutaneously as long as manual bladder evacuation was 
necessary. Manual bladder evacuation was performed twice a day until reflex bladder 
function returned, usually 7-10 days post-injury. Animals received either intraperitoneal (i.p.) 
injections of Epo D (Abcam, Cambridge, UK, cat.no.: ab143616) (1.5 mg/kg body weight) 
dissolved in DMSO (3 mg/ml) and diluted 1:1 with prewarmed saline immediately prior to 
injections (Epo D group, n= 18) or vehicle (1:1 mixture of DMSO and saline, control group, 
n=16) on day 1 and 15 post-injury (at an equivalent time of the day as the SCI surgery was 
performed on the previous day) by a blinded, unbiased experimenter, who was not involved in 
any of the behavioral testing and histological analysis. The Epo D concentration used in this 
study was based on data for Epo B and Epo D in clinical cancer studies and recent dosing 
regimes in rodents (Brunden et al., 2010). Epo B is administered in a dose range between 2.5 
and 50 mg/m
2
, whereas Epo D is administered in a dose range between 50 and 100 mg/m
2
(Beer et al., 2007; Lee and Kelly, 2009). Based on these data doubling of the Epo B dose used 
in the previous study (0.75 mg/kg body weight) with two administration time points (day 1 
and 15) (Ruschel et al., 2015) seemed most promising.  
One animal of each cohort was excluded due to inadequate force impact curves upon spinal 
cord contusion. Based on the variability in spinal cord displacement and the importance of 
displacement on functional parameters, animals were divided into 2 groups dependent on the 
injury-induced spinal displacement prior to Epo D administration and any functional testing. 
We chose a cut off at a displacement value of 1000 µm allowing for equal distribution of 
animals into 2 cohorts (low displacement; low dis <1000 µm and high displacement; high dis 
>1000 µm). These animals were then assigned to receive either vehicle or Epo D treatment
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(control low dis; n=8; Epo D low dis: n=8; control high dis: n=7; Epo D high dis: n=9) 
(Fig. 1). Animals were sacrificed 8 weeks post injury. 
Behavioral assessment 
Hindlimb motor function was evaluated according to the Basso, Beattie, Bresnahan (BBB) 
open field locomotor rating scale (Basso et al., 1995). BBB scores range from 0 to 21 (0 = no 
observable hindlimb movement, 21 = normal locomotion). All animals had a score of 0 at day 
1 post-injury (BBB assessment was always performed in the morning one day prior to the Epo 
D or vehicle injection on day 0 and day 14). From this time point, animals were scored once a 
week during the first 4 weeks and thereafter every two weeks by two independent blinded 
observers. A 7-point BBB subscore was additionally included for the 4 and 8 week time 
points, to evaluate higher motor functions (toe clearance, paw position, trunk stability and tail 
point (Lankhorst, 1999). However, only a selected number of the animals were evaluated for 
the parameters required for the BBB subscore (toe clearance, paw position, trunk stability and 
tail position):  at 4 weeks: control low dis: n=6; Epo D low dis: n=7; control high dis n=2; 
Epo D high dis: n=9; at 8 weeks: control low dis: n=8; Epo D low dis: n=8; control high 
dis n=5; Epo D high dis: n=8. 
To examine more subtle differences in locomotor function, the horizontal ladder walking test 
was performed. Animals were first trained to cross a 100-cm-long horizontal ladder with 
unevenly spaced rungs (1-3 cm) toward the home cage one week prior to the first testing. The 
test was carried out in the afternoon at 4 and 8 weeks post-injury (animals had a minimum of 
3 h between BBB testing and the horizontal ladder test to keep fatigue to a minimum). 
Additionally, rats were tested on a horizontal ladder with evenly spaced rungs (1 cm spacing) 
8 weeks post injury. The animals were recorded using a digital video camera, and 
performance was subsequently analyzed in slow motion by a blinded observer. The total 
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number of steps and the number of footfalls below the plane of the ladder (failure to place the 
hindlimbs on the rungs) were quantified in five uninterrupted crossings. The number of 
missteps per trial was counted, given as a percentile of the total number of steps, and averaged 
for five trials, by a blinded observer. Naive animals show typically < 10% missteps on the 
horizontal ladder with unevenly spaced rungs versus < 1% with evenly spaced rungs.  
For gait analysis, rats were tested 8 weeks after injury on an automated gait analysis system 
(CatWalk; Noldus, Oberreifenberg, Germany). Recorded footprints of 5 compliant runs were 
processed automatically using device specific software quantifying step distance of hindlimbs 
(stride length) and interpaw coordination (regularity index: the observed difference from 
normal step sequence patterns; base of support (BOS): average width between either the front 
paws or the hind paws). 
Tissue processing and immunohistochemistry 
Animals were transcardially perfused with 0.9% saline solution followed by 4% 
paraformaldehyde in 0.1 M phosphate buffer at 8 weeks post injury. The spinal cords were 
dissected, post-fixed overnight and cyroprotected in 30% sucrose. An 8 mm long block of the 
thoracic spinal cord including the lesion site and an adjacent 6 mm long block of the 
thoracolumbar spinal cord were cut into 30 μm thick coronal sections and directly mounted 
onto superfrost slides and processed for immunohistochemistry. Sections were collected in 14 
series resulting in equally spaced sections with a distance of 420 μm between adjacent 
sections on each slide. Three animals (one from the Epo D low dis, one from the control low 
dis and one from the control high dis cohort) had to be excluded from all histological 
analysis, due to technical problems during cryo-sectioning.  
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Eriochrome cyanine stain for spared myelin 
Eriochrome cyanine (EC) staining was used to identify myelinated areas in the thoracic spinal 
cord (Kigerl et al., 2007). Briefly  s i al   rd se  i  s  re i  sl  s  red a  −8 °  were air-
dried for 1–2 h at 37 °C in a dry incubator. After incubation with acetone for 5 min, the slides 
were air-dried for 20 min and then stained in EC solution (0.2% eriochrome cyanine R; Merck 
Millipore), 0.5% H2SO4, 10% iron alum in distilled water for 30 min, followed by a 5-min 
rinse in tap water. Stained sections were then differentiated for 5-20 min in 5% iron alum, 
which was followed by a 10-min rinse in tap water. Afterwards, sections were placed in 
borax-ferricyanide solution (1% borax, 1.25% potassium ferricyanide in distilled water) for 
10 min. After another 5 min rinse in tap water slides were dehydrated through a graded 
ethanol series and coverslipped using Neomount (Merck Millipore, Darmstadt, Germany). 
The total cross-sectional area of the spinal cord and the inner border of spared white matter 
were measured by an observer blinded to group identity on digitized images of the cord using 
an open image analysis program (Fiji2) (Schindelin et al., 2012). The digital images of EC-
stained sections were obtained using an Olympus BX53 microscope equipped with a XC 
camera. White matter was defined as the area that was stained for EC and considered spared if 
the myelin stain was dense, contiguous, and primarily normal in appearance with absence of 
cavities and minimal gliosis. The lesion area was identified by the loss of EC staining as well 
as severe tissue disruption. The injury epicenter was defined visually as the spinal cord 
section with the smallest visible rim of spared myelin. The spared white matter area (WMA) 
was measured in every 14
th
 section with a distance of 420 μm between adjacent sections. To
calculate the volume of spared white matter, the area of WMA of all sections was added 
before multiplying it with the series (14) and the thickness of the cut sections (30 µm). 
Immunohistochemistry 
Double/triple immunofluorescence labeling techniques were performed with direct-mounted 
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sections to assess fibrotic scaring and total length of 5-HT positive fibers in vivo. Sections 
were washed in TBS, blocked in TBS/5% donkey serum (GE Healthcare)/0.25% Triton X-
100 for 1 h and incubated with primary antibodies in TBS/1% donkey serum/0.25% Triton X-
100 overnight at 4 °C. The following day, sections were rinsed in TBS/1% donkey serum and 
incubated with Alexa Fluor 594 or Alexa Fluor 488 donkey secondary antibodies for 2.5 h 
(1:300; Life Technologies; cat. no.: A21207 and A21202 respectively). Sections were cover-
slipped with Fluoromount G (Southern Biotech, Birmingham, AL, USA). The following 
primary antibodies were used: mouse anti-GFAP for astroglia (1:1000; Merck Millipore; cat. 
no.: MAB360), rabbit anti-laminin (1:800; Sigma-Aldrich, Taufkirchen, Germany; cat. no.: 
L9393), rabbit-anti 5-HT (serotonin, 1:2000; Immunostar, Hudson, USA; cat. no.: 20080), 
mouse anti-ßIII-tubulin (1:1000; Promega, Mannheim, Germany; cat. no.: G7121), rabbit 
anti-fibronectin (1:500, Abcam; Cambridge, UK; cat. no.: ab2413) and DAPI as a nuclear 
counterstain.  
Measurement of fibrotic scar area 
Fibrotic scarring was quantified by measuring the laminin immunolabeled area in a complete 
series (interval between analyzed sections 420 µm). The laminin positive areas of all sections 
from the series were summed up. Based on the thickness of sections (30 µm) and the number 
of sections (14), the laminin positive volume was calculated (summed area x 30 µm x 14 = 
volume). The summed area was calculated either for the whole distance of the 8 mm block 
(4200 µm rostral to 4200 µm caudal), and shorter distances around the lesion center (2520 
µm, 840 µm and 420 µm rostral to caudal). 
Measurement of 5-HT positive fibers 
The total length of 5-HT positive fibers in the ventral horn was measured caudal to the injury 
site and the mean of the right and left ventral horn was taken. Three sections with a 420 µm 
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interval between sampled sections were taken from a caudal spinal cord block 2-4 mm caudal 
to the lesion epicenter. In addition, a spinal cord block located 4 to 10 mm caudal to the lesion 
epicenter corresponding to spinal level T12-L1, identical to the region examined previously, 
(Ruschel et al., 2015) was sectioned and 7-8 sections with 840 µm interval between sampled 
sections were analyzed. Images of the entire right and left ventral horn were taken using a 20x 
magnification and a zoom factor of 1.5x with a confocal microscope (FluoView FV1000, 
Olympus) with an optical thickness of 15 µm (7.5 µm above and 7.5 µm below the middle of 
the section). The images were saved as merged z-stacks. Images were further processed in 
Fiji2 by applying the Robust Automatic Threshold Selection (RATS) before skeletonizing the 
images. In these images the total skeleton length was automatically measured.  
Statistics 
All data are presented as mean ± standard error of the mean (SEM). Differences between 
groups were investigated using a parametric unpaired t-test (   de  ’s  -test). A two-way 
ANOVA was performed for analyzing data from BBB and irregular horizontal ladder testing, 
followed by post hoc     err  i’s multiple comparisons test. All statistical analyses were 
performed using PRISM6 software (GraphPad, San Diego, CA, USA). 
Results 
Differential tissue displacement generates distinct injury severity cohorts 
Following a 150 kDyn T9 contusion injury in adult female Fischer 344 rats, 
displacement curves were examined for consistency. The Infinite Horizon (IH) impactor is 
controlled by force usually resulting in consistent displacement of a given directed force, 
although some variation can occur. Because both force and displacement lead to anatomical 
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changes and as a consequence affect functional outcomes after contusive SCI (Ghasemlou et 
al., 2005), it is important to examine tissue displacement in addition to the actual force 
applied (Scheff et al., 2003; Zhang et al., 2008). In the present study, a 150 kDyn moderate 
contusion injury with the IH impactor generated two distinct displacement cohorts, one with 
less than 1000 µm displacement (low dis) and one with more than 1000 µm displacement 
(high dis). Prior to the first Epo D injection and prior to functional testing of animals, 
subjects were matched based on the displacement and divided into animals receiving Epo D 
or vehicle (control) treatment (Fig. 2 A). The actual force applied was not found to be 
significantly different between the cohorts (Fig. 2 B).  
Post-hoc analysis revealed significant differences in functional impairment between 
the control low dis and control high dis cohorts. Scores for hindlimb motor function assessed 
by BBB were always higher in the control low dis cohort, but were only significantly 
different at 3 week post injury (Fig. 2 C), However, horizontal ladder testing as well as the 
histological parameter for spared white matter were significantly worse in the high dis control 
cohort compared to the low dis control cohort (Fig. 2 D-E), confirming that an average 
difference in displacement of 177 µm indeed results in two distinct injury severities. 
Systemic Epo D administration promotes improvement in locomotor function  
Systemic i.p. administration of 1.5 mg/kg of Epo D at 1 and 15 days post-injury did 
not yield any obvious adverse effects, which is in line with previous Epo B and Epo D studies 
(Barten et al., 2012; Brunden et al., 2010; Ruschel et al., 2015; Zhang et al., 2012). After a 
transient injury-induced weight loss, animal weight increased over time in the treatment as 
well as the control groups irrespective of displacement severity (Supplementary Fig. 1).  
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Locomotor function was assessed by rating over-ground locomotion in an open field 
(BBB) or analysis of sensorimotor coordination by quantifying the number of footfalls across 
a regularly and irregularly spaced horizontal ladder. Moreover, instrumented over-ground gait 
analysis was performed with the Noldus Catwalk system. BBB locomotor scoring revealed 
complete hindlimb paralysis at day 1 post-injury. Thereafter, significant spontaneous 
improvement of hindlimb motor function was observed over time in all cohorts. Epo D 
treatment did not result in a superior recovery in BBB scores in either of the displacement 
cohorts although a slight trend towards better recovery was evident in Epo D cohort with the 
high displacement (Fig. 3 A, B). 
To evaluate recovery of higher motor functions such as toe clearance, paw position, 
trunk stability and tail position we determined the BBB subscore for a subset of animals. 
However, the BBB subscore showed no difference between groups similar to what we 
observed with the overall BBB score (BBB subscore 28 days: control low dis: 3.17 ± 0.95; 
Epo D low dis: 4.5 ± 0.89, p = 0.18; control high dis: 2.5 ± 0.50; Epo D high dis: 0.31 ± 
0.06 mm
3
, p = 0.45; BBB subscore 54 days control low dis: 4.25 ± 0.41; Epo D low dis:
4.81 ± 0.60, p = 0.45; control high dis: 2.8 ± 0.73; Epo D high dis: 3.4± 0.35, p = 0.39). 
Irregular ladder crossing, reflecting a more complex walking task, did reveal 
significant differences between control and Epo D treated animals within the high dis cohort 
at 4 and 8 weeks post-injury (Fig. 4 C, D). Epo D treated animals made fewer missteps in 
comparison to control animals on the irregular ladder (control high dis: 4 weeks: 64.74 ± 
4.98%; 8 weeks: 51.32 ± 3.36%; Epo D high dis: 4 weeks: 48.59 ± 5.88%, 8 weeks: 32.34 ± 
3.78%, *p < 0.05, Fig. 4 C). In the low dis cohort, significant changes were not detected at 
either time point (control low dis: 4 weeks:  32.72 ± 4.86%; 8 weeks: 24.49 ± 3.31%; Epo D 
low dis: 4 weeks: 31.76 ± 6.5%; 8 weeks: 20.09 ± 4.29%, Fig.4 A).  
Injured animals made very few missteps on the less challenging horizontal ladder test 
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with regularly spaced rungs at 8 weeks post injury. In the low dis cohort, less than 1% of the 
steps across the ladder were recorded as footfalls in both the Epo D and control cohorts (Fig. 
4 B). In the high dis cohort, the Epo D treated animals displayed 68% fewer footfalls 
compared to the control cohort (control high dis 8.8 ± 2.73%; Epo D high dis 2.79 ± 0.7, *p 
< 0.05, Fig. 4 D).  
In the gait analysis using the Catwalk system, which was performed at the end of the 
study at 8 weeks post-injury, no differences in commonly applied gait parameters such as the 
regularity index (the observed difference from normal step sequence patterns), stride length 
and base of support were observed between the Epo D or controls in either displacement 
cohort (Supplementary Fig. 2).  
Systemic Epo D does not modify structural changes occurring after contusion SCI 
To better understand which changes led to the functional benefits observed with Epo 
D, the pathological hallmarks of tissue sparing, fibrotic scarring, lesion extent and raphespinal 
innervation, which were previously positively modulated by paclitaxel and Epo B (Hellal et 
al., 2011; Ruschel et al., 2015), were examined.  
As a measure of neuroprotection, white matter sparing was analyzed in eriochrome 
cyanine (EC)-stained coronal sections spanning the lesion site over a distance of 4 mm rostral 
and 4 mm caudal to the epicenter. White matter sparing at the epicenter was not significantly 
different between Epo D treated animals compared to control animals in either of the 
displacement cohorts (Fig. 5 A, B, E, F, G, J). White matter sparing at different rostro-caudal 
distances in respect to the epicenter and the volume of spared white matter over the entire 
length of the lesion also remained unchanged in Epo D versus control cohorts, irrespectively 
of the displacement cohort (Fig. 5 C, D, H, I). Taken together, Epo D administration did not 
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improve white matter sparing although there seems to be a slight trend of higher white matter 
sparing at the epicenter in EpoD treated animals in the high displacement cohort.  
To investigate if Epo D modulates the fibrotic scar, the laminin positive area at the 
lesion site was analyzed. Again, a displacement effect was observed, since the laminin 
immunoreactive area/volume in the low dis cohort was reduced compared to the high dis 
cohort (Fig. 6 A-H). However, Epo D treatment did not change the laminin immunolabeled 
area in the epicenter (control low dis: 0,262 ± 0,06 mm
2
; Epo D low dis: 0,205 ± 0,03 mm
2
,
p = 0,416; control high dis: 0,322 ± 0,07 mm
2
; Epo D high dis: 0,234 ± 0,05 mm
2
, p =
0,305) or the overall laminin positive volume analyzed over a distance of 4 mm rostral and 4 
mm caudal to the epicenter (Fig. 6 C, D, G, H). We further performed an exploratory cut off, 
where we calculated laminin immunoreactivity within fractions of the total volume, namely in 
a volume confined to the lesion core (420 µm rostral and caudal to the epicenter). From there, 
we expanded to two larger volumes covering 840 µm and 2520 µm rostral and caudal to the 
epicenter, respectively. None of these fractioned volumes yielded significant differences 
between control and Epo D treated animals (420 µm cut off: control low dis: 0.291 ± 0.08 
mm
3
; Epo D low dis: 0.264 ± 0.04 mm
3
, p = 0.75; control high dis: 0.422 ± 0.07 mm
3
; Epo
D high dis: 0.31 ± 0.06 mm
3
, p = 0.246; 840 µm cut off: control low dis: 0.465 ± 0.09 mm
3
;
Epo D low dis: 0.408 ± 0.06 mm
3
, p = 0.62; control high dis: 0.406 ± 0.11 mm
3
; Epo D
high dis: 0.50 ± 0.09 mm
3
, p = 0.19; 2520 µm cut off: control low dis: 0.66 ± 0.13 mm
3
;
Epo D low dis: 0.534 ± 0.032 mm
3
, p = 0.45; control high dis: 1.006 ± 0.21 mm
3
; Epo D
high dis: 0.748 ± 0.14 mm
3
, p = 0.31). Additional characterization of the fibrous scar with
fibronection immunohistochemistry yielded specific and circumscribed labeling of the 
meninges but very diffuse staining in the spinal parenchyma, which did not differ 
qualitatively in between groups  (Supplementary Fig. 3). Moreover, astroglial morphology 
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around the lesion center was not overtly altered after EpoD treatment (Supplementary Fig. 
4). 
To examine potential effects on axonal sprouting or regeneration, serotoninergic (5-
HT) axon length was quantified caudal to the lesion epicenter, where a respective treatment 
effect would be most likely detectable. However, Epo D did not alter the total length of 5-HT 
axons compared to control animals directly caudal to the lesion in either displacement cohort 
(Fig. 7 A-J). It should also be noted that 5-HT fiber length was not significantly different in 
the control animals of the high dis cohort compared to the low dis cohort, unlike all other 
parameters measured (Fig. 7 E, J). To find out whether 5-HT sprouting in more caudal gray 
matter areas may have accounted for the observed functional improvement after Epo D 
treatment in the high dis cohort, 5-HT immunolabeled fibers were analyzed in the ventral gray 
matter of a more caudal spinal cord block corresponding to spinal level L1 containing rostral 
motoneurons projecting to hindlimb muscles. Again, the 5-HT fiber length was not found to 
be significantly different between Epo D treated and control animals (control high dis: 0.114 
± 0.02 mm; Epo D high dis: 0.09 ± 0.02 mm, p = 0.5077). 
Discussion 
In addition to the disruption of ascending and descending pathways, secondary injury 
mechanisms involving Wallerian degeneration and the formation of a fibroglial scar 
contribute to the functional deficits after SCI. Previous studies indicate that the administration 
of the microtubule-stabilizing drugs (paclitaxel and Epo B) result in reduced fibrotic scar 
formation, less axonal dieback and improvements in functional recovery after moderate SCI 
(Hellal et al., 2011; Ruschel et al., 2015).  
The present study demonstrates a clear improvement in skilled hindlimb locomotor 
function after systemic administration of Epo D in a moderate rat contusion SCI model. This 
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study aimed to examine the robustness of the effects of Epo D treatment, an Epo B analog 
with a better safety profile, following a spinal cord contusion injury. For comparison of our 
study with previous work, we utilized similar structural and functional readouts as previous 
reports (Ruschel et al., 2015). We retained the study length (8 weeks), timing of drug delivery 
(i.p. injection at 1 and 15 days post injury) and the injury model (150 kDyn contusion at the 
Th9 vertebral level). Due to variability in spinal cord displacement, our study was also able to 
examine the effects of Epo D on two distinct lesion severities. In addition to the structural 
outcomes (tissue preservation, fibrous scar formation and serotoninergic (5-HT) axon density) 
and the functional assays (regular ladder testing and Catwalk analysis) examined previously, 
we also evaluated BBB locomotor scores and a more complex irregular ladder task.   
To establish the concentration of Epo D to be administered in the current study (1.5 
mg/kg), previous work in a mouse model of tauopathy served as a starting point. Weekly i.p. 
injections of 3 mg/kg BW of Epo D for 3 months (Brunden et al., 2010), a dose equivalent to 
about 10 % of what was used in phase II clinical trials (Beer et al., 2007), were found to be 
more effective than a lower dose of 1 mg/kg BW. Furthermore, Epo D was found to cross the 
blood brain barrier and remains detectable in the brain 10 days after a single i.p. injection, 
whereas it is cleared rapidly from plasma (Brunden et al., 2011; Brunden et al., 2010). Even 
treatment with a higher dose or long-term application of Epo D for 15 months did not result in 
obvious side effects (Andrieux et al., 2006; Barten et al., 2012; Brunden et al., 2010). With 
consideration for allometric scaling, 3 mg/kg BW in the mouse would be equivalent to 1.5 
mg/kg BW in the rat (Nair and Jacob, 2016). Taken together, these findings suggest that the 
administered Epo D dose is within an efficient range without incurring secondary effects.  In 
fact, obvious adverse effects such as weight loss were not observed in the current study.  
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Analysis of spinal cord displacement records for each contused animal revealed 
considerable variability despite the equal force that was applied. Consistent with previous 
findings, rats with a similar impact force but a lower displacement (<1000 µm) showed better 
hindlimb sensorimotor function (BBB score) (Ghasemlou et al., 2005). Because the extent of 
displacement greatly affects injury severity (Ghasemlou et al., 2005), animals were divided 
into two cohorts dependent on injury-induced spinal displacement with a cut off at 1000 µm. 
A careful review of surgical records for all animals did not reveal any systematic errors, 
which could explain the variability in spinal cord displacement. All surgeries were performed 
by the same experimenter and anesthesia was kept constant for all animals. There was no bias 
in respect to time or day when contusions were performed. Animals with a low dis performed 
significantly better on the horizontal ladder and had significantly more spared white matter 
tissue compared to animals with a high dis. These results suggest that in an impactor-induced 
spinal cord contusion model, both force and displacement are important to determine the 
lesion severity and thus the functional outcome, further justifying our a priori separation into 
two distinct cohorts.  
Even though all animals revealed a spontaneous improvement of hindlimb motor 
function over time in the BBB score, no differences could be detected between Epo D treated 
and control animals, irrespective of the displacement severity. More subtle locomotor deficits, 
which are not detectable by the BBB score can be evaluated with the horizontal ladder test, in 
particular with unevenly spaced rungs. Indeed, Epo D treatment elicited superior performance 
(37% less missteps) in irregular spaced ladder crossing in the high dis cohort at 8 weeks post 
injury. As opposed to previous work investigating Epo B effects after SCI (Ruschel et al., 
2015), this functional benefit was not paralleled by increased serotonergic axon sprouting 
(raphespinal tract) caudal to the lesion. In the study by Ruschel et al. animals had to cross an 
evenly spaced ladder enabling them to utilize a given gait possibly representing a less 
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challenging locomotor task (Metz and Whishaw, 2009), which would require limited 
suprasegmental modulation due to minor perturbations. However, crossing an irregular ladder 
as in the present study depends upon not only descending propriospinal and supraspinal 
pathways but also upon sensory input via ascending tracts to adjust for perturbations caused 
by the unevenly spaced rungs (Filli et al., 2014; Kjell and Olson, 2016; Metz and Whishaw, 
2009; Schucht et al., 2002; Vogelaar and Estrada, 2016).  
The present study cannot confirm sprouting of 5-HT fibers - either at the caudal border 
of the lesion site or even further caudal in the region of motor neuronal pools relevant for 
locomotor function – as a structural correlate of the observed functional improvement on the 
horizontal ladder in contrast to previous studies (Hellal et al., 2011; Ruschel et al., 2015). 
Although many studies have associated sprouting of serotonergic fibers with sensorimotor 
recovery after SCI, ablation of serotonergic fibers with 5,7-dihydrotryptamin in spinal cord 
injured rats did not significantly alter locomotor function, measured by the BBB score, even 
though the study indicates that parts of the raphespinal system might still be important for 
some of these locomotor functions (Li et al., 2004). Other studies have shown that different 
descending tracts are also involved in crossing a horizontal ladder. Not only ventrolateral 
tracts, which are important for inter-limb coordination, but also reticulospinal axons to initiate 
stepping and corticospinal together with rubrospinal tracts for the control of voluntary 
movement are involved in performing such a complex task (Brustein and Rossignol, 1999; 
Jordan, 1998; Metz et al., 2000; Muir and Whishaw, 2000; Schucht et al., 2002). Thus, 
descending pathways other than raphespinal axons (Brustein and Rossignol, 1999; Jordan, 
1998; Metz et al., 2000; Muir and Whishaw, 2000) as well as newly formed propriospinal 
relays (Bareyre et al., 2004; Courtine et al., 2008; Filli et al., 2014; van den Brand et al., 
2012) might have contributed to the observed improvement. However, respective pathways 
were not analyzed in the present study. Thus, a structural neuroanatomical correlate for the 
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observed functional improvement cannot be presented at this point. In the low dis cohort 
neither the regular nor the irregular spaced ladder detected a difference between Epo D versus 
control animals, which is likely attributable to ceiling effects caused by near complete 
spontaneous functional recovery.   
One other important factor that might influence structural and functional outcomes 
after microtubule stabilization is the difference in sensitivity of various axonal tracts to Epo 
D. It has been previously shown that CNS neurons react differently to epothilone than PNS
neurons (Jang et al., 2016), suggesting that different degrees of microtubule stabilization 
might be needed in different axons for optimal axonal growth. Indeed, hyperstabilization of 
microtubules may lead to deficits rather than increased regeneration (Erturk et al., 2007; 
Sengottuvel et al., 2011). More work needs to be done to define the dose of Epo D best suited 
for our high dis lesion and whether other concentrations might provide more benefit after 
other lesion severities. 
Species and strain differences may also account for different outcomes between the 
current and previous studies. Rat strains and even sub-strains differ in terms of functional 
recovery and tissue sparing after SCI (Kjell and Olson, 2016; Mills et al., 2001; Webb et al., 
2003). Given our data that Epo D treatment results in different outcomes depending upon the 
lesion severity it can be hypothesized that with the same contusion force in rats ranging in a 
10-30% difference in animal weight (in the present study inbred Fischer 344 rats weighing
around 160-180 g were used, whereas in the previous study outbred Sprague Dawley rats 
weighing around 200-250 g were used) may affect injury severity and thus may result in a 
differential response to treatment. 
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Consistent with previous findings, where treatment with Epo B or paclitaxel did not 
affect the overall lesion size after contusion SCI (Hellal et al., 2011; Popovich et al., 2014; 
Ruschel et al., 2015), we did not observe any effect of Epo D on white matter sparing in 
Eriochrome cyanine-stained sections.  
As opposed to paclitaxel and Epo B (Hellal et al., 2011; Popovich et al., 2014; Ruschel 
et al., 2015), Epo D did not modify laminin expression around the lesion site. In the present 
study, laminin immunoreactive areas were measured in equidistant coronal sections over a 
distance of 8 mm covering the lesion site as well as the intact area beyond the lesion site, 
whereas in studies investigating paclitaxel and Epo B (Hellal et al., 2011; Popovich et al., 
2014; Ruschel et al., 2015), sagittal sections were analyzed only covering the lesion site 
(about 5 mm), which may have contributed to the observed differences. However, even after 
analyzing more confined volumes, approximating the 5 mm distance analyzed previously, 
laminin expression was still not significantly altered by Epo D. Alternatively, as mentioned 
above, strain differences or differential drug effects/concentrations may account for the 
differential effects on laminin expression. Finally, the effect of the drug may vary depending 
on the injury severity as described previously (Popovich et al., 2012a; Popovich et al., 2012b). 
Conclusions 
Overall, the present study revealed functional improvement after Epo D 
administration, comparable to the benefit observed in previous studies investigating the 
microtubule stabilizing drugs Epo B and paclitaxel (Hellal et al., 2011; Perez-Espejo et al., 
1996; Ruschel et al., 2015). However, the underlying structural correlates could not be clearly 
identified. Therefore, future experiments will expand the focus to relevant descending and 
ascending axonal pathways other than serotoninergic axons that may play a role in the 
functional recovery we observed. Subsequent experiments also need to investigate varying 
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concentrations, in conjunction with pharmacokinetic analysis and biomarker analysis to 
correlate spinal cord drug exposure with drug efficacy. 
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Figure Legends 
Figure 1: Experimental timeline. 
Rats received a spinal cord contusion injury at midthoracic level T9 using the Infinite Horizon 
(IH) Impactor SCI device with an impact force of 150 kDyn. At day 1 and 15 post injury, Epo 
D (1.5mg/kg) or vehicle (control) was injected i.p.. Starting one day post injury, animals were 
scored weekly using the BBB open field locomotor rating scale. At 4 and 8 weeks post injury, 
the horizontal ladder test was performed (4 weeks only irregular and 8 weeks irregular and 
regular spacing of rungs). At 57 days post injury, gait analysis using the Catwalk system was 
performed and animals were perfused afterwards.  
Figure 2: Cohort distributions. 
(A) Animals were a priori divided into 2 cohorts dependent on the injury-induced spinal
displacement (displacement of >1000 µm (high dis) or <1000 µm (low dis)). Animals with 
matching displacements were assigned to receive either vehicle or Epo D treatment (control 
low dis; n=8; Epo D low dis: n=8; control high dis n=7; Epo D high dis: n=9). Grey dotted 
line indicates the cut off at 1000 µm.    de  ’s  -test of low dis vs. high dis: ****p<0.0001. 
(B) Means of the actual force applied for the contusion injury revealed no overall differences
in impact forces.    de  ’s  -test of low dis vs. high dis: p=0.11. (C) BBB testing showed an 
improvement over time in both control cohorts (low dis or high dis). Control animals with a 
low dis have higher BBB score at all time points compared to control animals with a high dis, 
which did only reach significance at 21 days post injury (2-way ANOVA ****p<0.0001 for 
time, *p<0.05 for group comparison, post hoc     err  i’s multiple comparisons test, * 
p<0.05). (D) Horizontal ladder walking test crossing an irregular ladder was performed at 8 
weeks post injury. Control animals with a low dis made significantly fewer missteps 
compared to control animals with a high dis (   de  ’s  -test: *** p<0.001). (E) Spared white 
matter area at the epicenter was measured using eriochrome cyanine (EC) stained coronal 
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sections at 8 weeks post injury. Control animals with a low dis showed significantly more 
spared white matter area compared to control animals with a high dis (   de  ’s  -test: ** 
p<0.01). 
Figure 3: Assessment of over-ground gross locomotor function. 
Hindlimb motor function was evaluated according to the BBB open field locomotor rating 
scale. BBB testing did not reveal any group differences. BBB scores are shown in the (A) low 
dis (control low dis; n=8; Epo D low dis: n=8: 2-way ANOVA ****p<0.0001 for time, 
p=0.85 for group comparison) and (B) high dis cohort (control high dis n=7; Epo D high 
dis: n=9: 2-way ANOVA ****p<0.0001 for time, p=0.15 for group comparison) up to 8 
weeks post injury.  
Figure 4: Assessment of skilled walking on the regular and irregular ladder tests.  
Functional outcome on the horizontal ladder test were evaluated 4 and 8 weeks post injury (A, 
B: low dis: control low dis; n=8; Epo D low dis: n=8; C, D: high dis: control high dis n=7; 
Epo D high dis: n=9). Bar graphs showing the number of missteps given as a percentile of 
the total number of steps for the horizontal ladder with (A, C) irregularly or (B, D) regularly 
spaced rungs. Epo D treated animals with a high dis showed a significant reduction in the 
number of missteps in the irregular horizontal ladder at 4 and 8 weeks post injury (2-way 
ANOVA, ****p<0.0001 over time and ***p<0.001 for overall group differences, post hoc 
    err  i’s multiple comparisons test, * p<0.05). Note that animals made fewer mistakes 
when crossing the regular compared to the irregular ladder. Epo D treated animals with a 
displacement of >1000 µm showed a significant reduction in missteps in the regular 
horizontal ladder test (   de  ’s  -test, *p<0.05).  
Figure 5: Tissue sparing and representative images of spinal cord cross-sections at the 
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lesion center. 
(A, B, F, G) Tissue sparing was measured using eriochrome cyanine (EC) stained coronal 
sections at the lesion center 8 weeks post injury (A-E: low dis: control low dis; n=7; Epo D 
low dis: n=7; F-J: high dis: control high dis n=6; Epo D high dis: n=9). Animals with a 
displacement <1000 µm have a greater rim of spared tissue compared to animals with a 
displacement greater than 1000 µm. Dorsal is to the top of the images. Scale bar: 250 µm. No 
apparent differences are visible between control animals (A, F) and Epo D-treated animals (B, 
G), independent of the displacement. (C, H) The area of spared white matter is shown 
between 4200 µm rostral and caudal to the epicenter. The lowest amount of tissue sparing is 
seen at the epicenter, gradually increasing with further distance from the epicenter. (D, I) 
Volume of spared white matter and (E, J) area of spared white matter at the epicenter did not 
differ between Epo D-treated and control animals at 8 weeks post injury     de  ’s  -test, low 
dis: p = 0.33; high dis p = 0.11).  
Figure 6: Fibrotic scar formation. 
(A, B, E, F) Laminin (red) and glial fibrillary acidic protein (GFAP; green) immunolabeling 
of coronal sections at the lesion center 8 weeks post injury (A-D: low dis: control low dis; 
n=7; Epo D low dis: n=7; E-H: high dis: control high dis n=6; Epo D high dis: n=9). Dorsal 
is to the top of the images. Scale bar, 250 μm. (C, G) The laminin positive area up to 
4200µm rostral and caudal to the epicenter decreases with further distance from the epicenter. 
(D, H) Scatter plot showing the laminin positive volume compared to control animals at 8 
weeks post injury. Animals with a displacement greater than 1000 µm have more laminin 
positive area than animals with displacement <1000 µm. Epo D treated animals show slightly 
reduced laminin positive volume, which does not reach significance (   de  ’s  -test, low dis: 
p = 0.61; high dis p = 0.22). 
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Figure 7: Total length of serotonergic (5-HT)-positive fibers in the ventral horn. 
(A-J) Serotonin (5-HT) immunolabeling 8 weeks post injury (A-E: low dis: control low dis; 
n=7; Epo D low dis: n=7; F-J: high dis: control high dis n=6; Epo D high dis: n=9). (A-D, 
G-I) Coronal sections of the spinal cord after spinal contusion injury. Note the beaded 5-HT
positive fiber appearance in higher magnification images of the boxed area of (A, B, F, G) 
shown in (C, D, H, I), respectively. Dorsal is to the top of the images. Scale bar (A, B, F, G): 
250 µm; (C, D, H, I): 100 µm. (E, J) Bar graphs showing the total length of 5-HT positive 
fibers in the ventral horn of evenly spaced sections caudal from the lesion epicenter. The 
values of each the right and left ventral horn of 3 consecutive sections were averaged and 
plotted as means ± SEM. The total length of 5-HT positive axons was not significantly 
increased in Epo D treated animals in either displacement cohort     de  ’s  -test, low dis: p = 
0.31; high dis p = 0.73).  
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